Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergey Shcherbinin

Showing results (51-60 of 74) with videos related to

Pageof 8
Sort By:
Alzheimer'S & Dementia (New York, N. Y.)|February 22, 2021
Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's diseaseJennifer A Zimmer, Sergey Shcherbinin, Michael D Devous, et al.
Nature Communications|April 5, 2020
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's diseaseShorena Janelidze, Erik Stomrud, Ruben Smith, et al.
EJNMMI Research|March 16, 2020
PET quantification of brain O-GlcNAcase with [<sup>18</sup>F]LSN3316612 in healthy human volunteersJae-Hoon Lee, Jeih-San Liow, Soumen Paul, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 7, 2025
Quantitation of PET spatial extent as a potential adjunct to visual interpretation of [<sup>18</sup>F]flortaucipir imaging: TAU-SPEXEmma M Coomans, Bastiaan van Tol, Colin Groot, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 3, 2025
Correction to: Quantitation of PET spatial extent as a potential adjunct to visual interpretation of [<sup>18</sup>F]flortaucipir imaging: TAU-SPEXEmma M Coomans, Bastiaan van Tol, Colin Groot, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 29, 2023
The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partners Scientific Board (PPSB)Bruce Albala, Eline Appelmans, Ramona Burress, et al.
Nature Medicine|June 24, 2025
Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trialCorby K Martin, Owen T Carmichael, Susan Carnell, et al.
Brain : a Journal of Neurology|April 20, 2026
Neuropathological correlates of age and sex differences in 18F-flortaucipir PETEmma M Coomans, Ruben Smith, Daria Pawlik, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 4, 2026
Defining patient-centered amyloid PET thresholds for the onset of tauopathy in Alzheimer's diseaseZeyu Zhu, Anna Steward, Amir Dehsarvi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 9, 2025
Multimodal spatial gradients to explain regional susceptibility to fibrillar tau in Alzheimer's diseaseYing Luan, Lukai Zheng, Jannis Denecke, et al.
Pageof 8

Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
Alzheimer'S & Dementia (New York, N. Y.)|February 22, 2021
Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's diseaseJennifer A Zimmer, Sergey Shcherbinin, Michael D Devous, et al.
Nature Communications|April 5, 2020
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's diseaseShorena Janelidze, Erik Stomrud, Ruben Smith, et al.
EJNMMI Research|March 16, 2020
PET quantification of brain O-GlcNAcase with [<sup>18</sup>F]LSN3316612 in healthy human volunteersJae-Hoon Lee, Jeih-San Liow, Soumen Paul, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 7, 2025
Quantitation of PET spatial extent as a potential adjunct to visual interpretation of [<sup>18</sup>F]flortaucipir imaging: TAU-SPEXEmma M Coomans, Bastiaan van Tol, Colin Groot, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 3, 2025
Correction to: Quantitation of PET spatial extent as a potential adjunct to visual interpretation of [<sup>18</sup>F]flortaucipir imaging: TAU-SPEXEmma M Coomans, Bastiaan van Tol, Colin Groot, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 29, 2023
The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partners Scientific Board (PPSB)Bruce Albala, Eline Appelmans, Ramona Burress, et al.
Nature Medicine|June 24, 2025
Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trialCorby K Martin, Owen T Carmichael, Susan Carnell, et al.
Brain : a Journal of Neurology|April 20, 2026
Neuropathological correlates of age and sex differences in 18F-flortaucipir PETEmma M Coomans, Ruben Smith, Daria Pawlik, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 4, 2026
Defining patient-centered amyloid PET thresholds for the onset of tauopathy in Alzheimer's diseaseZeyu Zhu, Anna Steward, Amir Dehsarvi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 9, 2025
Multimodal spatial gradients to explain regional susceptibility to fibrillar tau in Alzheimer's diseaseYing Luan, Lukai Zheng, Jannis Denecke, et al.
Pageof 8